Table 3. Inpatient Characteristics, Medications, and Complications.
Patients receiving care at NYP/CUIMC ED were stratified according to the highest level of care received during their hospitalization. The intubated patient row includes all patients who were intubated at least once – they may be intubated, extubated, re-intubated, or dead. Extubated patients include only those who were successfully extubated, including patients who died later in their hospital course. It is important to note that 90 patients have not reached the end of their hospital course and that their charts continue to be reviewed. All categorical data is reported as a frequency and a column percentage [95% confidence interval]. All continuous data is reported as median (interquartile range). These are the outcomes reviewed as of April 30, 2020. ACEi, Angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inflammatory drugs.
| Overall (N = 1000) |
||||
|---|---|---|---|---|
| Currently in Hospital | 0 0% [0.0 – 2.5] |
3 0.5% [0.2 – 1.4] |
87 36.9% [31.0 – 43.2] |
90 9% [7.4 – 10.9] |
| Discharged | 128 85.3% [78.8 – 90.1] |
525 85.5% [82.5 – 88.1] |
46 19.5% [14.9 – 25.0] |
699 69.9% [67.0 – 72.7] |
| Died in Hospital | 22 14.7% [9.9 – 21.2] |
86 14% [11.5 – 17.0] |
103 43.6% [37.5 – 50.0] |
211 21.1% [18.7 – 23.7] |
| Intubated (at least once) | 12 8% [4.6 – 13.5] |
1 0.2% [0.0 – 0.9] |
220 93.2% [89.3 – 95.8] |
233 23.3% [20.8 – 26.0] |
| Extubated (at least once) | 1 0.7% [0.1 – 3.7] |
0 0% [0.0 – 0.6] |
74 31.4% [25.8 – 37.5] |
75 7.5% [6.0 – 9.3] |
| A Median Length of Stay in Days (IQR) | –––––––– | 4 (2 – 8) | 23 (12 −32) | 6 (3 – 14) |
| Inpatient Medications | ||||
| ACEi/ARBs | –––––––– | 32 5.2% [3.7 – 7.3] |
7 3% [1.4 – 6.0] |
39 4.6% [3.4 – 6.2] |
| NSAIDs | –––––––– | 89 14.5% [11.9 – 17.5] |
30 12.7% [9.1 – 17.6] |
119 14% [11.8 – 16.5] |
| Statins | –––––––– | 156 25.4% [22.1 – 29.0] |
62 26.3% [21.1 – 32.2] |
218 25.6% [22.8 – 28.7] |
| Diuretics | –––––––– | 73 11.9% [9.6 – 14.7] |
178 75.4% [69.6 – 80.5] |
251 29.5% [26.6 – 32.7] |
| Inotropes | –––––––– | 0 0% [0.0 – 0.6] |
30 12.7% [9.1 −17.6] |
30 3.5% [2.5–5.0] |
| Vasopressors | –––––––– | 16 2.6% [1.6 – 4.2] |
222 94.1% [90.3 – 96.4] |
238 28% [25.1 – 31.1] |
| Intravenous Immunoglobulin | –––––––– | 2 0.3% [0.1 – 1.2] |
5 2.1% [0.9 – 4.9] |
7 0.8% [0.4 – 1.7] |
| Steroids | –––––––– | 60 9.8% [7.7–12.4] |
118 50% [43.7–56.3] |
178 20.9% [18.3–23.8] |
| Hydroxychloroquine | –––––––– | 331 53.9% [50.0 – 57.8] |
212 89.8% [85.3 – 93.1] |
543 63.9% [60.6 – 67.0] |
| Tocilizumab | –––––––– | 13 2.1% [1.2 – 3.6] |
38 16.1% [12 – 21.3] |
51 6% [4.6 – 7.8] |
| Remdesivir | –––––––– | 7 1.1% [0.6 – 2.3] |
11 4.7% [2.6 – 8.2] |
18 2.1% [1.3 – 3.3] |
| Lopinavir/Ritonavir | –––––––– | 1 0.2% [0.0 – 0.9] |
1 0.4% [0.1 – 2.4] |
2 0.2% [0.1 – 0.9] |
| Any Antibiotics | –––––––– | 328 53.4% [49.5–57.3] |
224 94.9% [91.3–97.1] |
552 64.9% [61.7–68.1] |
| Azithromycin | –––––––– | 235 38.3% [34.5 – 42.2] |
170 72% [66.0 – 77.4] |
405 47.6% [44.3 – 51.0] |
| Ceftriaxone | –––––––– | 117 19.1% [16.1 – 22.4] |
84 35.6% [29.8 – 41.9] |
201 23.6% [20.9 – 26.6] |
| Doxycycline | –––––––– | 31 5% [3.6 – 7.1] |
19 8.1% [5.2 – 12.2] |
50 5.9% [4.5 – 7.7] |
| Levofloxacin | –––––––– | 7 1.1% [0.6 – 2.3] |
14 5.9% [3.6 – 9.7] |
21 2.5% [1.6 – 3.7] |
| Meropenem | –––––––– | 8 1.3% [0.7 – 2.5] |
72 30.5% [25.0–36.7] |
80 9.4% [7.6 – 11.6] |
| Piperacillin-Tazobactam | –––––––– | 66 10.7% [8.5 – 13.4] |
184 78% [72.3 – 82.8] |
250 29.4% [26.4 – 32.6] |
| Vancomycin | –––––––– | 28 4.6% [3.2 – 6.5] |
139 58.9% [52.5 – 65.0] |
167 19.6% [17.1–22.5] |
| Other Antibiotics | –––––––– | 49 8% [6.1 – 10.4] |
96 40.7% [34.6 – 47.0] |
145 17.1% [14.7 – 19.7] |
| Hospital Complications | ||||
| Acute Respiratory Distress Syndrome | –––––––– | 87 14.2% [11.6 – 17.2] |
212 89.8% [85.3 – 93.1] |
299 35.2% [32.0 – 38.4] |
| Acute Kidney Injury | –––––––– | 104 16.9% [14.2 – 20.1] |
184 78% [72.3 – 82.8] |
288 33.9% [30.8 – 37.1] |
| Inpatient Dialysis | –––––––– | 34 5.5% [4.0 – 7.6] |
83 35.2% [29.4 – 41.5] |
117 13.8% [11.6 – 16.2] |
| New Onset Arrhythmia | –––––––– | 17 2.8% [1.7–4.4] |
62 26.3% [21.1–32.2] |
79 9.3% [7.5 – 11.4] |
| Ventilator-Associated Pneumonia | –––––––– | 0 0% [0.0 – 0.6] |
58 24.6% [19.5 – 30.4] |
58 6.8% [5.3 – 8.7] |
| New Onset Heart Failure | –––––––– | 6 1% [0.4 −2.1] |
18 7.6% [4.9 – 11.7] |
24 2.8% [1.9–4.2] |
| Myocardial Infarction | –––––––– | 1 0.2% [0.0 – 0.9] |
7 3% [1.4 – 6.0] |
8 0.9% [0.5 – 1.8] |
| Mechanical Circulatory Support (ECMO) | –––––––– | 0 0% [0.0 – 0.6] |
5 2.1% [0.9 – 4.9] |
5 0.6% [0.3 – 1.4] |
Median length of stay (LOS) is calculated as days from admission to either discharge, death, or last chart review.